Cancer Research Pioneer Dr. H. Michael Shepard Joins Anpac Bio Technical Advisory Board

SACRAMENTO, Calif., Feb. 13, 2019 /PRNewswire/ -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation, Anpac Bio-Medical Science Company (Anpac Bio), announced today that reproductive cancer researcher and respected, innovative, therapeutics pioneer, Dr. H. Michael Shepard, is now an Anpac Bio Technical Advisory Board (TAB) Member.

Anpac Bio-Medical Science Company CEO Dr. Chris Yu, welcomed reproductive cancer researcher and respected, innovative, therapeutics pioneer, Dr. H. Michael Shepard, to the Anpac Bio Technical Advisory Board. Best known for initiating the team/research developing the cancer drug Herceptin, Dr. Shepard will be testing Anpac Bio’s breakthrough “Cancer Differentiation Analysis” (CDA) #liquidbiopsy technology for cancer screening, and to monitor recurrence following treatment.

The Indiana University and University of California, Davis alum is best known for initiating the novel, Genetech research team that discovered the antibody that attacks HER2-tumor cells – ultimately, stopping or killing them. This antibody, now called Trastuzumab (better known as "Herceptin"), substantially increases survival in breast, and some ovarian and gastric, cancer patients with large amounts of the HER2 protein on the surface of their tumor cells.

Multiple research studies confirm overall survival of HER2+ cancer patients 37% higher when treated with Herceptin plus chemotherapy; compared to patients given only chemotherapy. At ten years after treatment, disease-free survival was 40% better in patients treated with Herceptin plus chemotherapy, compared to those treated only with chemotherapy.

Since its introduction to the marketplace, Herceptin has dominated the HER2+ market, with market share well above 90%. Herceptin is projected to earn $9.89 Billion annually by 2025.

Among Shepard's other research accomplishments include:

  • Bringing the first adenovirus gene therapy into clinical trials (for ovarian cancer);
  • Creating small molecule cancer therapeutics, targeting cancer overexpressed following the inactivation of tumor suppressor genes;
  • Pioneering the concept of 'pan-HER' inhibition (single drug deterring the EGFR, HER2, and HER3);
  • Obtaining European and U.S. drug approval for EnhanzeTM technology for subcutaneous drug delivery, thus allowing patients to avoid the infusion clinic;
  • Creating a platform for discovering tumor specific therapeutics, such that patients can be selected based upon their proven ability to respond to a given therapy.

In recognition of his breakthrough research, the Warren Alpert Foundation and Harvard Medical School, presented Shepard the prestigious, "Warren Alpert Prize". The Warren Alpert Prize "honors scientists, physicians and researchers whose scientific achievements have led to the prevention, cure, or treatment of human diseases or disorders, and/or whose research constitutes a seminal scientific finding that holds great promise of ultimately changing our understanding of, or ability to treat, disease."

Shepard will be working with Anpac Bio studying the company's breakthrough, "Cancer Differentiation Analysis" (CDA) liquid biopsy technology's applications for reproductive cancer screening; and as companion diagnostics for cancer therapeutics.

Anpac Bio pioneered liquid biopsy research for cancer screening. Comprehensive research validity data from 130,000+ cases processed (to date), demonstrate CDA diagnostics consistently detects 28+ different cancers -- with 75%-90% sensitivity and specificity rates -- usually at the diseases' earliest stages. And it does so without any harmful patient side effects; generating far fewer "false positives"; at a cost, substantially lower than traditional testing (such as imaging); and generating results within minutes of sample submission. Anpac Bio has filed 250+ CDA-related patent applications worldwide – 107+ issued by 20 countries; (to date) and is fully-commercialized and earning liquid-biopsy screening revenue.

"Our Anpac Bio team is pleased to welcome Dr. Shepard to our Technical Advisory Board," states Dr. Yu. "It is due to Dr. Shepard's extensive, award-winning research experience, and reputation for identifying innovative solutions to fight disease, that prompted our invitation. We are excited Dr. Shepard will be testing our equipment against the current, traditional cancer screening methods; as well as advising us on how we can best support researchers and therapeutics developers. We look forward helping Dr. Shepard save many more lives in the months and years to come."

For further information:

Multi-award winning reproductive cancer researcher and therapeutics pioneer, Dr. H. Michael Shepard, joined CEO Dr. Chris Yu, Anpac Bio’s US Executive Team and fellow Technical Advisory Board (TAB) Members in Shanghai, China, inspecting Anpac Bio’s breakthrough, Cancer Differentiation Analysis #LiquidBiopsy technology research. Pictured left-to-right: CEO Dr. Chris Yu, TAB Dr. H. Michael Shepard, CFO Mark Luhdorff, CMO Drisha Leggitt, TAB Dr. John Reddington, TAB Dr. Lee Shulman & VP Sherry Yu.

International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" liquid biopsy technology that effectively reinvents cancer screening and early detection. Anpac Bio's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 120,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for 28+ different types of cancer -- often identifying the type and location of threatening, diseased cancer cells before they form into tumors. Fully-commercialized and the only company earning liquid biopsy revenue globally, Anpac Bio has filed 250+ CDA-related Patents; 101+ issued to date worldwide. For more information: (PRNewsFoto/Anpac Bio-Medical Science Co.)

Cision View original content to download multimedia:

SOURCE Anpac Bio-Medical Science Company

Back to news